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 Antiretrovirals fail to penetrate into HIV reservoirs in mesenteric lymphatic system
 Delivery of prodrugs and lopinavir to HIV reservoirs in lymphatic system
 Activated ester prodrug approach achieved the most efficient delivery of lopinavir
 This approach also improved the systemic exposure to lopinavir
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Abstract
The combined antiretroviral therapy (cART) can efficiently suppress HIV replication, but the
cessation of cART usually results in viral rebound, mostly due to the presence of viral
reservoirs. The mesenteric lymphatic system, including mesenteric lymph nodes (MLNs), is an
important viral reservoir into which antiretroviral drugs poorly penetrate. In this work, we
proposed a novel lipophilic ester prodrug approach, combined with oral lipid-based
formulation, to efficiently deliver lopinavir (LPV) to the mesenteric lymph and MLNs. A series
of prodrugs was designed using an in-silico model for prediction of affinity to chylomicrons
(CMs), and then synthesized. The potential for mesenteric lymphatic targeting and
bioconversion to LPV in physiologically relevant media was assessed in vitro and ex vivo.
Subsequently, LPV and selected prodrug candidates were evaluated for their in vivo
pharmacokinetics and biodistribution in rats. Oral co-administration of lipids alone could not
facilitate the delivery of unmodified LPV to the mesenteric lymphatic system and resulted in
undetectable levels of LPV in these tissues. However, a combination of the lipophilic prodrug
approach with lipid-based formulation resulted in efficient targeting of LPV to HIV reservoirs
in mesenteric lymph and MLNs. The maximum levels of LPV in mesenteric lymph were 1.6-
and 16.9-fold higher than protein binding-adjusted IC90 (PA-IC90) of LPV for HIV-1 (140
ng/mL) following oral administration of simple alkyl ester prodrug and activated ester prodrug,
respectively. Moreover, the concentrations of LPV in MLNs were 1.1- and 7.2-fold higher than
PA-IC90 following administration of simple alkyl ester prodrug and activated ester prodrug,
respectively. Furthermore, the bioavailability of LPV was also substantially increased
following oral administration of activated ester prodrug compared to unmodified LPV. This
approach, especially if can be translated to other antiretroviral drugs, has potential for reducing
the size of HIV reservoirs within the mesenteric lymphatic system.
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1. Introduction
The combined antiretroviral therapy (cART) can efficiently reduce viral load and keep it
undetectable in the blood of HIV-infected patients for the duration of treatment [1,2]. However,
as soon as the therapy is interrupted, rebound viremia can occur within a few weeks [3–5]. This
is partially due to the persistence of HIV-1 in anatomical and cellular viral reservoirs [6], which
are established during early primary infection stage [7–9] and are extremely stable even during
fully suppressive cART [10–14]. The gut-associated lymphoid tissue (GALT), including
mesenteric lymph and mesenteric lymph nodes (MLNs), harbors a large proportion of body’s
lymphocytes [15]. During primary HIV infection, severe CD4+ T cells depletion in GALT can
impair effective immune response against HIV-1, thereby contributing to poor clinical
outcomes [16,17]. Initiation of early cART can partially preserve and reconstitute immune
function [18], but does not prevent GALT eventually becoming one of the most important and
persistent anatomical reservoirs of HIV [13,19–21].
Unfortunately, presently known antiretroviral drugs poorly permeate into lymphoid tissues and
particularly low levels can be detected in MLNs, resulting in suboptimal concentrations in these
important viral reservoirs [12,13,20,22]. In the past, almost all attempts to enhance the delivery
of antiretroviral agents to lymph nodes (LNs) involved a general idea of subcutaneous or
intramuscular injection of different types of nano-sized drug delivery systems [22–25]. The
rationale for this common approach is that due to the nano-scale size of these drug delivery
systems, nanoparticles are taken up preferentially by the lymphatics rather than permeate into
blood capillaries. However, the main drawback of this common approach is that due to the
pattern of anatomical drainage of lymph from subcutaneous space or muscle, the drug could be
delivered only to peripheral LNs. Moreover, only those limited individual peripheral LNs
collecting the lymph fluid directly from the local region of injection site could be reached using
this approach.
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In this work, a physiological pathway of absorption of dietary lipids via intestinal lymphatic
transport was utilized for delivery of antiretroviral drug lopinavir (LPV) to the mesenteric
lymphatic system. It has been previously shown in multiple studies that highly lipophilic
compounds with appropriate physicochemical characteristics (Log D7.4 > 5, long-chain
triglyceride (LCT) solubility > 50 mg/mL) have substantial intestinal lymphatic transport when
administered orally with lipids [26,27]. Highly lipophilic compounds can associate with
chylomicrons (CMs), large lipoproteins which are assembled in the enterocytes in the presence
of long-chain triglyceride or long-chain fatty acids. CMs are too large to penetrate into blood
capillaries, and therefore are taken up preferentially by lymph lacteals together with the
associated highly lipophilic drugs. This mechanism promotes absorption of drugs into the
mesenteric lymphatic system before they reach the systemic circulation (Fig. 1) [15]. A linear
correlation between the in vivo lymphatic absorption of lipophilic compounds and the degree
of drug-CMs association in vitro has been previously reported [28]. Therefore, the degree of
drug-CMs association could be used as a useful tool to select potential candidates which are
likely to have intestinal lymphatic transport and therefore could be delivered to the mesenteric
lymph and MLNs in an efficient and selective manner.
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Previous studies from our and other groups showed efficient delivery of highly lipophilic
compounds to the mesenteric lymph and MLNs following oral administration with lipid-based
formulations [26,27,29,30]. For example, it was found that the levels of cannabidiol (CBD)
and Δ9-tetrahydrocannabinol (THC) in the mesenteric lymph were as high as 250- and 100-
fold higher in lymph than in plasma, respectively, when co-administered with long-chain
triglyceride formulation [30]. Moreover, it was also found that when the active drug does not
have sufficient lipophilicity for the intestinal lymphatic transport, a lipophilic prodrug approach
can still achieve efficient delivery of the drug to the mesenteric lymphatic system [29].
Recently, a number of clinically used protease inhibitors (PIs) were screened in vitro for their
potential for intestinal lymphatic transport in unmodified form. Only tipranavir (TPV) showed
some experimental association with CMs. However, in vivo results showed that the distribution
of chemically unmodified TPV to the mesenteric lymph was moderate and to MLNs was
minimal [31].
Fig. 1. Schematic diagram of delivery of LPV to the mesenteric lymphatic system.
Lipophilic prodrugs of LPV have high affinity to chylomicrons (CMs) in the enterocytes,
leading to intestinal lymphatic transport and high local concentrations in mesenteric lymph
and MLNs. LPV released from the prodrugs by enzymatic cleavage of the ester bond exerts
its pharmacological effect within the mesenteric lymph and MLNs.
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LPV has been consistently recommended as the preferred PI in second-line cART regimens
[32]. However, similar to most other PIs, LPV does not possess sufficient lipophilicity for
delivery to mesenteric lymph and MLNs without chemical modification [31]. Therefore, the
aim of this study was to design and synthesize lipophilic ester prodrugs that possess the
necessary physicochemical properties for improved association with CMs and lead to efficient
delivery of LPV to HIV reservoirs within the mesenteric lymph and MLNs. The efficiency of
bioconversion of inactive prodrugs to active agent (LPV) have been evaluated in
physiologically relevant media. Subsequently, candidates which possess moderate to high
affinity to CMs, good stability in conditions mimicking intestinal tract and rapid release to LPV
in conditions mimicking the lymphatic system have been selected for in vivo assessment.
Finally, the efficiency of the novel prodrug approach in targeting LPV to viral reservoirs in
mesenteric lymphatic system has been assessed in vivo in rats.
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2. Materials and method
2.1. Materials
Lopinavir (CAS: 192725-17-0) was purchased from Fisher Scientific (Leicestershire, UK), and
cannabidiol (CAS: 13956-29-1) from THC Pharm (Frankfurt, Germany). Intralipid®, porcine
liver esterases, propylene glycol, sesame oil, serum triglyceride determination kit, sodium
taurocholate (NaTc), lecithin, NaF, G418 (antibiotics), propidium iodide (PI) and puromycin
were all purchased from Sigma-Aldrich (Gillingham, UK or St. Louis, MO, USA).
Lipofectamine 2000, Roswell Park Memorial Institute (RPMI) 1640 medium and fetal bovine
serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA). Rat plasma was purchased
from Sera Laboratories (West Sussex, UK). The HIV Rev-dependent GFP (Green fluorescent
protein) indicator Rev-A3R5-GFP cells were provided by Virongy (Virginia, USA). The
infectious HIV-1 molecular clone pNL4-3 was obtained from the NIH AIDS Reagent Program.
HPLC analytical grade water was obtained from PURELAB® Ultra system (ELGA LabWater,
UK). All other research reagents used were of HPLC analytical grade or higher.
2.2. Chemistry
2.2.1. Design of LPV prodrugs
Prodrugs 1-5 were designed as simple alkyl esters. For prodrug 6, the enzymatic recognition
site (acetamide) was designed to be further away from the main scaffold for better access and
diketopiperazine cyclisation to liberate the drug LPV [33]. For prodrug 7, an electronegative
heteroatom (oxygen) was introduced in the β position relative to the acyl group [34]. Due to 
those specific features, compounds 6 and 7 will be referred in this paper as activated ester
prodrugs. Chemical structures of all synthesized prodrugs are shown in Fig. 2.
10
2.2.2. Prodrugs synthesis
The synthesis of ester prodrugs was based on previously reported chemical approach with slight
modifications [35]. Corresponding carboxylic acid to generate prodrugs 1-7 (1.59 mmol), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) (1.59 mmol) and 4-
dimethylaminopyridine (DMAP) (0.032 mmol) were dissolved in anhydrous dichloromethane
(DCM) (10 mL) and stirred at room temperature under N2 for 15 min before adding LPV (0.159
mmol). The reaction mixture was then allowed to stir overnight and monitored by TLC and
LC-MS. The mixture was added to saturated NH4CH3CO2 (30 mL), then extracted with ethyl
acetate (20 mL × 3). The combined organic layers were washed with saturated NaHCO3 (30
mL) and brine (30 mL), then dried over anhydrous MgSO4, filtered, and the solvent evaporated
in vacuo. The crude product was purified by column chromatography on silica using a gradient
DCM/tetrahydrofuran (THF) 5:1. The purified fractions were pooled and fully evaporated to
dryness. Final compound (20 mg) was dissolved in DMSO-d6 for NMR analysis. The detailed
methodology of characterization of the purified prodrugs is described in Supplementary
Material 1.
2.3. In vitro and ex vivo CMs association assay
2.3.1. Preparation of artificial emulsion (Intralipid®)
Intralipid® 20% was diluted with phosphate buffered saline (PBS, PH 7.4) to yield a
triglyceride (TG) concentration of 1 mg/mL [36]. TG concentration was measured by serum
TG determination kit using manufacturer’s instructions (Sigma-Aldrich).
2.3.2. Isolation of human plasma-derived CMs
The protocol for preparation of human plasma-derived CMs was approved by the Faculty of
Medicine and Health Sciences Research Ethics Committee, Queens Medical Centre,
Nottingham University Hospitals (BT12102015 CBS SoP). Three healthy male participants
between 30-40 years old were enrolled after providing informed consent. Study participants
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received a high-fat breakfast (equivalent to a full English breakfast [29]). Three to four hours
following the meal, 30 mL of blood was collected into heparinised Vacutainer® blood
collection tubes, and plasma was separated by centrifugation (800 g, 10 min, 15°C).
The separation of CMs from human plasma was performed as previously described [28,29]. A
density of 1.1 g/mL was achieved by gently mixing 4 mL of plasma with KBr (0.57 g). Standard
solutions with densities of 1.006, 1.019 and 1.063 g/mL were prepared by dissolving
appropriate amounts of KBr in PBS. Density gradient was built by layering standard solutions
of different densities on the top of plasma in a 12-mL polyallomer ultracentrifuge tube. Samples
were ultracentrifuged (SORVALL® Ultracentrifuge; TH-641 Rotor, 268,350 g, 35 min, 15°C)
and the upper layer (approximately 1 mL) containing CMs fraction, was collected by glass
Pasteur pipettes. TG concentrations were measured using the serum TG determination kit and
were adjusted to 1 mg/mL TG level by PBS of 1.006 g/mL density. Standard human CMs from
each volunteer were separately stored at 4°C for less than 24 h before association assay.
2.3.3. Association assay
Stock solutions of tested compounds (0.1 mM) were prepared in propylene glycol with 1%
ethanol (v/v). An appropriate volume of stock solution was spiked into 1 mL of previously
prepared artificial emulsion or human CMs (1 mg/mL TG) to obtain a final concentration of
tested compounds of 1.75 µM [28]. The mixture was incubated at 37°C with magnetic stirring
at 170 rpm. Following 1 h incubation, 0.9 mL of the mixture was added into 0.157 g of KBr to
achieve a density of 1.1 g/mL. A density gradient was then built using PBS buffers with the
density of 1.036, 1.019 and 1.006 g/mL. The CMs fraction was isolated by gradient density
ultracentrifugation as described above and stored at -80°C until analysis.
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2.4. Prodrug conversion assay
The release of LPV from the prodrugs was assessed in rat plasma and fasted state simulated
intestinal fluids (FaSSIF, pH = 6.5) supplemented by esterases (mixture of esterases from
porcine liver, mainly carboxylesterase, at 20 IU/mL) [29,37,38]. The preparation of FaSSIF
was performed as previously reported [39]. Following pre-incubation at 37°C for 5 minutes,
stock solution of tested compound (1 mM) in acetonitrile was spiked into the media to reach a
final concentration of 10 µM. The mixture was incubated at 37°C, 200 rpm on a temperature-
controlled orbital shaker (Thermo Scientific MaxQ4000, Waltham, MA, USA). One hundred
microliters of the incubation mixture was withdrawn at pre-determined time points, and
reaction was terminated by 300 µL of cooled (-20°C) acetonitrile containing 10 µL of internal
standard (IS). The samples were analysed for the prodrug and LPV concentrations by means
of HPLC-UV as described below. All experiments were performed in triplicates.
2.5. In vitro antiretroviral activity assay
2.5.1. Cell culture and virus preparation
HIV Rev-dependent GFP indicator cells Rev-A3R5-GFP [40] were cultured in RPMI 1640
plus 10% FBS supplemented with 1 μg/ml G418 and 1 μg/ml puromycin. To produce HIV-1 
particles, HEK293T cells were transfected with 20 μg of the infectious HIV-1 molecular clone 
pNL4-3 using Lipofectamine 2000 in 100 mm cell culture dish. Virus-containing supernatant
was collected at 48 h post transfection and filtered through a 0.45 μm nitrocellulose membrane.  
2.5.2. Viral infection assay
For each infection, 0.3 million Rev-A3R5-GFP cells were infected with HIV-1 (NL4-3) for 2
h (150 ng p24 per infection). Cells were then washed twice and cultured in fresh media which
was spiked with the working standard solutions of LPV and its prodrugs (in DMSO) to yield
concentrations of 10-3, 10-2, 10-1, 100, 101, 102, 103, 104 nM. The percentage of GFP+ cells was
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quantified by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA) at 72 h
post infection [41].
2.5.3. Prodrug stability in cell culture media
The stability of prodrugs was assessed in cell culture media (RPMI 1640 + 10% FBS). Stock
solution of tested compound (1 mM) in DMSO was spiked into the media to yield a final
concentration of 10 µM. The mixture was incubated at 37°C for 72 h to mimic the time frame
of the antiretroviral activity assay. One hundred microliters of the incubation mixture were
withdrawn at 48 and 72 h, and proteins were precipitated by 300 µL of cooled (-20°C)
acetonitrile. The samples were analysed for the prodrugs and LPV concentrations by means of
HPLC-UV as described below. All experiments were performed in triplicates.
2.6. TG solubility test
Tested compounds were weighed (> 5 mg) and added into sesame oil (100 µL) with constant
mixing using a magnetic stirrer at 37°C for 72 h. Samples were then centrifuged in Costar Spin-
X Centrifuge Tubes (Fisher Scientific, Loughborough, UK) at 2400 g for 20 min. The collected
supernatants were diluted with ethanol (1:104, v/v) and analysed by means of HPLC-UV. All
experiments were performed in triplicates.
2.7. Animal experiments
2.7.1. Animals
Animal welfare and all experimental procedures were reviewed and approved by the University
of Nottingham Ethical Review Committee under the Animals [Scientific Procedures] Act 1986.
Male Sprague Dawley rats (330-380 g) were obtained from Charles River Laboratories UK and
housed at Bio Support Unit, University of Nottingham. Animals were kept in an
environmentally controlled room (12:12 h light-dark cycle) with free access to food and water
for at least six days before starting any procedures.
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2.7.2. Pharmacokinetic study
Jugular vein catheterization surgery procedures were performed under surgical inhalation
anaesthesia (2.5% isoflurane in oxygen) by implantation of silastic-polyethylene (PE-50)
tubing into the right external jugular vein [29,42]. The animals were allowed to recover for two
nights before pharmacokinetic experiment. Prior to the experiment day, rats were fasted
overnight with free access to water. For intravenous bolus administration, LPV, prodrugs 1 and
7 were solubilised in a mixture of propylene glycol–sterile water–ethanol (70:20:10, v/v/v) at
concentrations of 4 mg/mL, 10 mg/mL and 2.37 mg/mL, respectively. Formulations (1 mL/kg)
were injected intravenously within 30 seconds via the jugular vein catheter followed by 0.3 mL
heparinised saline (50 IU/mL). For oral administration of LPV in lipid-free group, the
formulation was prepared by dissolving LPV in 100% propylene glycol (20 mg/mL). For oral
administration of LPV in lipid-based group, LPV solubilised in 100% propylene glycol (20
mg/mL) was co-administered with fresh sesame oil (1 mL/kg) due to the low solubility of LPV
in TG. For oral administration of prodrugs in lipid-based groups, prodrugs were solubilized in
fresh sesame oil at concentrations equivalent to 20 mg/mL of LPV. All oral formulations were
administered by an oral gavage (1 mL/kg), followed by 1 mL of water. Blood samples (0.25
mL) were withdrawn via the jugular vein catheter before dosing and at pre-determined time
points following administration. Eppendorf tubes contained EDTA (1.5 M) to prevent blood
coagulation and NaF (10 mg/mL) as an esterase inhibitor. Blood samples were placed on ice
immediately following the collection for no longer than 5 min and plasma was separated by
centrifugation (3000 g, at 0°C for 3 min) and stored at -80°C until analysis (except prodrug 7
which was analysed immediately). At the end of pharmacokinetic study, rats were euthanised
by CO2 inhalation, and MLNs, liver, spleen, brain and testes were harvested and stored at -
80°C until analysis. The concentrations of LPV and prodrugs in plasma and tissues were
determined by means of HPLC-UV. Non-compartmental analysis (NCA) was applied to
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calculate pharmacokinetic parameters derived from plasma concentration-time profiles using
Phoenix WinNonlin 6.3 software (Pharsight, Mountain View, CA, USA). The oral










Rats were fasted overnight with free access to water. Lipid-based formulations of tested
compounds were prepared as described above on the day of the administration. Following oral
administration of LPV or prodrugs, rats were euthanised by CO2 inhalation at plasma tmax and
tmax-1. Lymph sample was immediately collected from the mesenteric lymph duct. The MLNs
were collected as previously reported [29,30]. Briefly, mesenteric tissues were removed from
the abdominal cavity and placed in a clean weigh boat and MLNs were gently isolated from
mesenteric adipose tissue. Other tissues, including spleen, brain, liver, and testes were also
harvested, and stored at -80°C until analysis. All the collected tissues were homogenized
(POLYTRON® PT 10-35 GT, Kinematica AG, Luzern, Switzerland) with NaF in water (10
mg/mL) (1:3, w/v) on ice bath prior to sample preparation for drug analysis. The drug and TG
levels in the harvested lymph samples were analysed on the day of collection.
2.8. Analytical procedures
2.8.1. Sample preparation
All samples (plasma, lymph and tissue homogenates) underwent the same procedure of protein
precipitation and liquid-liquid extraction for HPLC-UV analysis [43]. Ten microliters of IS
was added to 100 μL sample, followed by 300 μL of cooled (-20°C) acetonitrile for protein 
precipitation and 300 μL of HPLC-grade water. A volume of 3 mL n-hexane–ethyl estate (7:3, 
v/v) was added as extraction solvent, then the mixture was vortex-mixed for 3 min followed by
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centrifugation (1160 g, 10°C, 10 min). Following centrifugation, organic layer was transferred
to a fresh tube and evaporated to dryness under nitrogen at 40°C (Techne DRI- Block type DB-
3D, Cambridge, UK). Dry residue was reconstituted in 100 μL of 50% acetonitrile in water, 
vortex-mixed for 10 min, transferred to HPLC vials and 40 μL were injected into the HPLC 
system. The validation of prodrugs stability during sample preparation is described in
Supplementary Material 1.
2.8.2. Chromatography conditions
The HPLC-UV system consisted of a Waters Alliance 2695 separations module equipped with
a Waters 996 photodiode array detector. The temperature of autosampler was maintained at
4°C and the column was kept at 40°C. Complete HPLC running conditions for all tested
compounds including column, guard column and mobile phase are described in Supplementary
Material Table S1. Empower™ 2 software was used for data acquisition and analysis.
2.9. Statistical analysis
The data are shown as mean ± standard deviation (SD). Statistical analysis between two data
sets was performed by two-tailed unpaired t-test. One-way ANOVA followed by Dunnett’s or
Tukey’s test was used to compare between three or more data sets. A p-value lower than 0.05
was considered to represent a significant difference. Statistical analysis was performed using
GraphPad Prism version 7.04 (GraphPad Software, Inc., La Jolla, CA, USA).
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3. Results
3.1. Prodrug synthesis and structural characterisation
All designed ester prodrugs were synthesized and purified. Calculated physicochemical
parameters used for in-silico prediction of association with CMs, as well as predicted values of
affinity to CMs and water solubility are shown in Table 1. The schematic presentation of the
chemical synthetic route and the chemical structures of prodrugs are shown in Fig. 2. The
characterisation of individual molecules is available in Supplementary Material 2. Prodrugs 1-
5 were alkyl esters with a short to medium chain fatty acid. The activated ester prodrugs 6 and
7 were then designed and synthesized following the assessment of prodrugs 1-5.
Fig. 2. Chemical structures of LPV and its prodrugs. Prodrugs 1-5 are short to medium
chain fatty acid alkyl esters; Prodrugs 6 and 7 are activated esters which should promote
more rapid release of LPV in the lymphatic system. EDCI, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide; DMAP, 4-dimethylaminopyridine; DCM,
dichloromethane; RT; room temperature.
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Table 1. Physicochemical parameters of LPV and its prodrugs used for in-silico prediction of association with CMs, as well as predicted


















LPV 5.88 0.38 120 9 15 1.163 540.4 4 54.6 2.1
1 6.82 1.26 126.07 10 19 1.141 612.4 3 69.6 2.9
2 8.96 0.19 126.07 10 21 1.126 645.4 3 97.4 0.007
3 9.83 0.38 126.07 10 23 1.112 678.4 3 99.2 0.00049
4 10.77 0.5 126.07 10 25 1.1 711.4 3 99.8 0.00017
5 11.54 0.79 126.07 10 27 1.089 744.5 3 99.9 0.000027
6 4.84 0.74 184.27 14 21 1.194 657.3 5 16.7 18
7 7.61 0.84 135.3 11 22 1.139 651.8 3 88.5 0.069
Physicochemical parameter values were obtained using ACD I-Lab. CMs, chylomicrons; PSA, polar surface area; FRB, freely rotatable bonds; LPV, lopinavir
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3.2. Uptake of LPV and its prodrugs by CMs
The association of LPV and prodrugs 1-7 with artificial and natural CMs is shown in Fig. 3A.
There was no uptake of unmodified LPV and prodrug 6 by CMs. Prodrugs 1-5 and 7 showed
moderate to high affinity to CMs, indicating substantial potential for delivery of these prodrugs
to the mesenteric lymphatic system following oral administration with lipid-based formulation.
As shown in Fig. 2, the leaving groups of prodrugs 1-4 are short (4 carbons) to medium (10
carbons) chain fatty acids. The longer the fatty acid chain, the higher was the affinity to CMs
for prodrugs 1-4. However, further increase in the lipophilicity and molecular weight by
addition of the C12 chain fatty acid (prodrug 5) resulted in reduction in affinity to CMs,
suggesting that there is a defined lipophilicity and molecular weight range which leads to
optimal association with CMs.
Fig. 3. In vitro and ex vivo assessment for LPV and its prodrugs. (A) The association (%) of
LPV and its prodrugs with human chylomicrons and artificial emulsion (Intralipid®),
representing their potential for the delivery to the mesenteric lymphatic system (n = 5). The final
concentration of each tested compound in incubation media was 1.75 µM [28]; (B) The
degradation half-lives of the respective prodrugs in fasted state simulated intestinal fluid
(FaSSIF) with added esterases (20 IU/mL) and in rat plasma, representing the stability of
prodrugs in the intestinal tract and lymphatic system, respectively (n = 3). Two-tailed unpaired
t-test was used for statistical analysis, *, p < 0.05; ***, p < 0.001. (C) The relative percentage
of released active drug LPV from its corresponding prodrugs in rat plasma (n = 3). Data are
expressed as mean ± SD.
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3.3. In vitro and ex vivo biotransformation of prodrugs
In this study, the stability of prodrugs and release of the active drug LPV were conducted in rat
plasma and fasted state simulated intestinal fluid with added esterase activity (FaSSIF,
representing intestinal tract environment). Plasma contains similar composition and levels of
enzymes to lymph fluid in many species (including humans and rats) [44,45]. Therefore, rat
plasma was chosen as an acceptable surrogate to represent lymph fluid in these studies. Similar
approach was implemented in previous work by us [29] and other groups [46,47].
The degradation half-lives of the respective prodrugs in both matrixes are shown in Fig. 3B.
The degradation half-lives of prodrug 3 in FaSSIF, as well as prodrugs 4 and 5 in both matrixes
could not be reliable calculated due to their extremely high stabilities. Alkyl ester prodrug 1
showed efficient release of LPV in plasma compared to prodrugs 2 and 3 (Fig. 3C). Activated
ester prodrugs 6 and 7 were substantially less stable in plasma than alkyl ester prodrugs. In
particular, prodrug 7 was relatively stable in FaSSIF (half-life: 17.3 ± 3.0 h) but rapidly
converted (half-life: 0.16 ± 0.02 h) to LPV in plasma (Fig. 3B and 3C). This is in line with
previous literature suggesting that insertion of a heteroatom in the 3rd position (β position) of 
acyl moiety in the carboxyl esters can enhance plasma and lymph carboxylesterases (CEs)
sensitivity [34]. Based on combined CMs association data, plasma and intestinal stability
assessments, prodrugs 1 and 7 were selected for subsequent antiretroviral activity and in vivo
pharmacokinetics and biodistribution studies.
3.4. Antiretroviral activities of LPV and selected prodrugs
The 50% inhibition concentration (IC50) of LPV and selected prodrugs against HIV-1 (NL4-3)
were derived from released GFP signals where the cell lines responded to infectious HIV-1
stimuli (Supplementary Material Fig. S1). The IC50 of both prodrugs increased after chemical
modification, compared to that of unmodified LPV (Fig. 4A). This, combined with the data of
LPV release from prodrugs in cell culture media (Fig. 4B and 4C), suggests that efficient
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release of active drug from prodrugs is necessary for pharmacological effect of LPV to take
place in the lymphatic system.
3.5. Triglyceride solubility of LPV and selected prodrugs
Triglyceride (TG) solubility was tested for LPV and prodrugs selected for in vivo studies. The
TG solubility for LPV and prodrug 7 were 1.8 ± 0.1 and 24.2 ± 1.4 mg/mL, respectively (mean
± SD, n = 3). Prodrug 1 solubility was above 50 mg/mL (n = 3).
3.6. Plasma pharmacokinetics of LPV and selected prodrugs
The in vivo plasma pharmacokinetic profiles of LPV and its prodrugs were obtained following
intravenous and oral (in lipid-free and lipid-based formulation) administrations in rats (Fig. 5).
The pharmacokinetic parameters derived from these plasma concentration-time profiles are
shown in Table 2 and Table 3. A significant difference between half-lives of LPV was
observed in oral lipid-based group versus intravenous or oral lipid-free group (Fig. 5A and 5B;
Table 2), suggesting flip-flop kinetics following oral administration in lipidic formulation,
Fig. 4 Assessment of the antiretroviral efficacy of LPV and selected prodrugs. (A) In
vitro anti-HIV-1 activity of LPV and its prodrugs following 72 h incubation. Inhibition
curves and IC50 were generated from plotting relative infectivity (%) against drug
concentrations using GraphPad Prism version 7.04; (B) The relative percentage of prodrugs
remaining; (C) the relative percentage of released LPV from its corresponding prodrugs in
cell culture media at 48 and 72 h. Data are shown as mean ± SD, n = 3.
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most probably due to delayed gastric emptying [48]. The oral bioavailability values of LPV
were not significantly different between oral administrations of LPV in lipid-free and lipid-
based groups (Table 2).
A long elimination half-life of prodrug 1, as well as relatively low levels of released LPV
following single intravenous bolus administration of prodrug 1 have been observed in plasma
(Fig. 5C and Table 3). The very long circulation time of prodrug 1 was also observed in plasma
up to 3 days when dosed orally, indicating there could be a re-distribution of this lipophilic
prodrug between plasma and deep tissue compartments. Importantly, in parallel with prolonged
systemic exposure to prodrug 1, a continuous release of LPV was observed in plasma (Fig. 5D).
Oral administration of short alkyl ester prodrug 1 resulted in relatively high bioavailability of
unchanged prodrug (Table 3). However, the absolute bioavailability of released LPV was
lower than following administration of unmodified LPV (Table 2), most probably due to slow
release of LPV from the prodrug.
On the other hand, in case of activated ester prodrug 7, the elimination half-life of prodrug in
systemic circulation was extremely short following single intravenous bolus administration
(Fig. 5E and Table 3). When prodrug 7 was orally administered with lipids, only the released
LPV could be detected in systemic blood circulation (Fig. 5F), suggesting that the ester bond
of prodrug 7 was rapidly hydrolyzed, and most probably while still in the lymphatic system.
This is in agreement with the rapid release of active drug in plasma ex vivo (Fig. 3C). The oral
bioavailability of released LPV following oral administration of prodrug 7 was nearly 2-fold
higher than following administration of unmodified LPV in lipid-free formulation or with lipids
(Table 2).
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Fig. 5. Plasma pharmacokinetic profiles of LPV and selected prodrugs in rats. Plasma
concentration-time curves following: (A) intravenous bolus administration of LPV (4
mg/kg, n = 4); (B) oral administration of LPV in lipid-free formulation and with lipids (20
mg/kg, n = 4); (C) intravenous administration of prodrug 1 (10 mg/kg, n = 3); (D) oral
administration of prodrug 1 in lipid-based formulation (equivalent to 20 mg/kg of LPV, n =
7); (E) intravenous administration of prodrug 7 (equivalent to 2 mg/kg of LPV, n = 3); (F)
oral administration of prodrug 7 in lipid-based formulation (equivalent to 20 mg/kg of LPV,
n = 6). Data are expressed as mean ± SD.
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Table 2. Plasma pharmacokinetic (PK) parameters of LPV following administration of LPV and its prodrugs to rats (mean ± SD).
PK parameters of LPV following
administration of LPV
PK parameters of LPV following
administration of prodrug 1
PK parameters of LPV following
administration of prodrug 7
Route of
administration







i.v. (n = 3)
p.o. (in lipids,
n = 7)
i.v. (n = 3)
p.o. (in lipids,
n = 6)b
AUCinf (h·ng/mL) 2176 ± 403 2483 ± 649 2231 ± 396 232 ± 44 - 2913 ± 261 4100 ± 731
AUC0→t (h·ng/mL) 2157 ± 407 2419 ± 676 2031 ± 375 144 ± 23 1163 ± 677 2884 ± 253 3868 ± 714
C0 or Cmax (ng/mL) 5171 ± 1796 920 ± 360 591 ± 112 63 ± 7 50 ± 26 3421 ± 385 927 ± 181
tmax (h) - 3.0 ± 0.0 3.5 ± 1.0 0.3 ± 0.1 4.3 ± 1.0 - 3.3 ± 1.0
t1/2 (h) 0.4 ± 0.1 0.8 ± 0.2 1.5 ± 0.6** 3.1 ± 2.0 96.6 ± 72.4 1.6 ± 0.3 2.8 ± 0.6
Vss (L/kg) 1.18 ± 0.41 - - - - - -
CL (L/h/kg) 1.89 ± 0.36 - - - - - -
Foral (%) - 22.8 ± 6.0c 20.5 ± 3.6c - 10.8 ± 6.3d - 37.3 ± 6.7c **
AUCinf, area under the curve from time zero to infinity; AUC0→t, area under the curve from time zero to the last sampling time point; C0, concentration extrapolated to time
zero; Cmax, maximum observed concentration; tmax, time to reach peak concentration; t1/2, half-life; Vss, volume of distribution at steady state; CL, clearance; Foral, oral
bioavailability.
a One-way ANOVA followed by Dunnett’s test was used for statistical analysis, **, p < 0.01 compared to t1/2 obtained following i.v. administration of LPV.
b One-way ANOVA followed by Tukey’s test was used for statistical analysis, **, p < 0.01 compared to Foral (%) obtained following p.o. administration of LPV in lipid-
free formulation and with lipids.
c Calculated based on the AUCinf.
d Calculated based on the AUC0→t.
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Table 3. Plasma pharmacokinetic (PK) parameters of prodrugs 1 and 7 following administration of LPV prodrugs to rats (mean ± SD).
PK parameters of prodrug 1 following
administration of prodrug 1
PK parameters of prodrug 7 following
administration of prodrug 7
Route of administration i.v. (n = 3)
p.o. (in lipids,
n = 7)
i.v. (n = 3)
p.o. (in lipids,
n = 6)
AUCinf (h·ng/mL) 8210 ± 407 - 1061 ± 290 -
AUC0→t (h·ng/mL) 6631 ± 443 10208 ± 4077 1056 ± 292 -
C0 or Cmax (ng/mL) 17857 ± 2680 220 ± 110 33701 ± 9384 -
tmax (h) - 3.6 ± 0.8 - -
t1/2 (h) 64.5 ± 1.3 - 0.3 ± 0.1 -
Vss (L/kg) 48.09 ± 5.69 - 0.10 ± 0.04 -
CL (L/h/kg) 1.22 ± 0.06 - 2.34 ± 0.61 -
Foral (%)a - 69.3 ± 27.7 - -
AUCinf, area under the curve from time zero to infinity; AUC0→t, area under the curve from time zero to the last sampling time point; C0, concentration extrapolated to time
zero; Cmax, maximum observed concentration; tmax, time to reach peak concentration; t1/2, half-life; Vss, volume of distribution at steady state; CL, clearance; Foral, oral
bioavailability.
a Calculated based on the AUC0→t
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3.7. Biodistribution of LPV and selected prodrugs
For the assessment of drug distribution to the mesenteric lymph and MLNs following oral
administration, tmax observed in plasma during pharmacokinetic studies and 1 h before tmax (tmax-
1) were considered as the two important sampling time points. As previously reported [29,30],
the levels of drugs in mesenteric lymphatic system are usually higher at tmax-1, compared to tmax.
In addition to the mesenteric lymph and MLNs, other tissues representing important HIV
reservoirs were harvested and analysed for prodrugs and LPV concentrations at the same time
points, as well as following the completion of the pharmacokinetic studies (Fig. 6). The
concentrations of LPV were below the limit of detection in both mesenteric lymph and MLNs
following administration of unmodified LPV, even in presence of lipids (Fig. 6A). However,
high TG levels were observed in mesenteric lymph fluid (Supplementary Material Fig. S2).
This indicates that despite the fact that lipids were efficiently absorbed, unmodified LPV could
not be delivered to the mesenteric lymphatic system even when co-administered with
lymphotropic lipids.
On the other hand, oral administration of prodrug 1 in lipid-based formulation resulted in high
levels of the prodrug in the mesenteric lymphatic system (Fig. 6B and 6C). The concentrations
of prodrug 1 were 52- and 55-fold higher in mesenteric lymph and MLNs, respectively,
compared to plasma at tmax-1 (Fig. 6B), whereas relatively low levels of released LPV were
observed (Fig. 6C). Although the concentrations of prodrug 1 were substantially higher in
mesenteric lymph and MLNs compared to plasma, slow release of active drug in lymphatic
system seems to be the limitation of simple alkyl ester prodrug approach.
Following oral administration of activated ester prodrug 7 in lipid-based formulation, high
concentrations of the prodrug were observed in mesenteric lymph and MLNs (Fig. 6D), which
is in line with its high affinity to CMs (approximately 50%) (Fig. 3A). Importantly,
administration of prodrug 7, featuring an oxygen in the β position relative to the acyl group, 
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led to an impressive improvement of delivery of active LPV to the mesenteric lymphatic system.
The levels of LPV in mesenteric lymph and MLNs following oral administration of prodrug 7
were 10.3- and 6.8-fold higher, respectively, compared to administration of prodrug 1 (Fig. 7A
and 7B). Importantly, the levels of LPV were above the protein binding-adjusted IC90 (PA-IC90)
(140 ng/mL) in both lymph fluid and MLNs for both prodrugs. The maximum levels of LPV
in mesenteric lymph were 1.6- and 16.9-fold higher than PA-IC90 of LPV for HIV-1 (140
ng/mL) following oral administration of simple alkyl ester prodrug and activated ester prodrug,
respectively. The concentrations of LPV in MLNs were 1.1- and 7.2-fold higher than PA-IC90
following administration of simple alkyl ester prodrug and activated ester prodrug, respectively.
Moreover, substantial levels of released LPV were observed in MLNs even at 12 h following
oral administration of prodrug 7 (Fig. 6E). Therefore, this approach not only leads to the
delivery of the prodrug to the mesenteric lymphatic system, but also to efficient release of the
active drug LPV at the site of action within this viral reservoir.
It should be noted that high levels of LPV and prodrugs could be also detected in liver following
oral administrations of LPV and prodrugs (Fig. 6). The concentrations of prodrug 1 (but not
prodrug 7) were detectable in spleen (Fig. 6B), but no LPV could be detected in this tissue (Fig.
6C) following oral administration of prodrug 1. Interestingly, the levels of LPV could be
observed in spleen at tmax after administration of prodrug 7 (Fig. 6E), probably due to improved
systemic exposure to LPV (Fig. 5F and Table 2). The drug levels in other harvested tissues
representing viral reservoirs (such as brain and testes) were below the limit of detection.
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Fig. 6. Biodistribution profiles of LPV and selected prodrugs. Rats were administered a
20 mg/kg LPV-equivalent dose of LPV, prodrugs 1 and 7 with lipids by an oral gavage.
Biodistribution profiles of (A) LPV following administration of unmodified LPV (n = 4);
(B) prodrug 1 and (C) released LPV from prodrug 1 following administration of prodrug 1
(n = 8); (D) prodrug 7 and (E) released LPV from prodrug 7 following administration of
prodrug 7 (n = 4). Data are expressed as mean ± SD. Plasma concentrations were generated
in pharmacokinetic studies. MLNs, mesenteric lymph nodes. One-way ANOVA followed
by Dunnett’s test and two-tailed unpaired t-test were used for statistical analysis, *, p <
0.05, **, p < 0.01, ***, p < 0.001.
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Fig. 7. Maximum concentrations of LPV in mesenteric lymphatic system.
Concentrations of LPV in (A) mesenteric lymph fluid (ng/mL) and (B) MLNs (ng/g) were
obtained following oral administration of LPV (n = 4), prodrugs 1 (n = 8) and 7 (n = 4) with
lipids during biodistribution studies. Limit of detection for lymph fluid and MLNs were 100
ng/mL and 80 ng/g, respectively. The dotted line represents the plasma PA-IC90 of LPV
(140 ng/mL). Data are expressed as mean ± SD (***, p < 0.001 by two-tailed unpaired t-
test). MLNs, mesenteric lymph nodes. PA-IC90, protein binding-adjusted concentration
required for 90% viral inhibition.
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4. Discussion
The GALT (including mesenteric lymphatic system) is the largest viral reservoir in HIV-
infected individuals [13,19–21]. Limited penetration of antiretroviral drugs to the mesenteric
lymphatic system is a significant barrier for HIV eradication from these important viral
reservoirs [12,13,20,22]. In this study, we aimed to deliver antiretroviral drug (LPV) to the
mesenteric lymph and MLNs by novel lipophilic ester prodrug approach. The rationale behind
this approach is based on physiological process of intestinal lipid absorption and transport.
4.1. LPV prodrugs with high potential for delivery to mesenteric lymphatic system
Initially, we assessed the potential of unmodified LPV for intestinal lymphatic transport. The
affinity of drugs to CMs is usually highly predictive for intestinal lymphatic transport in vivo
[28,36]. Although in-silico modelling predicted moderate affinity of LPV to CMs (Table 1),
the experimental association of the drug with CMs was negligible, in accordance with the
relatively low experimental lipophilicity (log P = 1.7 [49]). Therefore, increasing the
lipophilicity of the molecule by adding fatty acid to form ester prodrugs was considered a
reasonable approach to promote high affinity to CMs. We chemically masked the polar and
ionisable hydroxyl group within the LPV scaffold to obtain highly lipophilic alkyl ester
prodrugs. Results indicate that increasing the lipophilicity dramatically improved the degree of
association with CMs by 30% to 50%, compared to the unmodified LPV (Fig. 3A). Previous
studies demonstrated that the increased association of highly lipophilic prodrugs with CMs
resulted in efficient delivery of drugs to the mesenteric lymph and MLNs, compared to the
unmodified moderately lipophilic active drug [29].
4.2. In vitro screening and selection of prodrug candidates for in vivo studies
In order to efficiently deliver drugs to the mesenteric lymphatic system by a prodrug approach,
two critical factors have to be considered in the process of prodrug design and assessment. First,
the ideal prodrug should have good chemical and enzymatic stability in the gastrointestinal
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tract prior to absorption. Second, the prodrug should rapidly and efficiently release the active
drug as soon as it reaches the lymphatic system. The good stability of prodrugs in FaSSIF (Fig.
3B) suggests that all these prodrugs are likely to remain at least partially intact in the intestinal
tract before they reach the enterocytes where association with CMs takes place. Therefore,
given the similar stability of all synthesized prodrugs in this study in the intestinal environment,
the stability in rat plasma (as an appropriate surrogate to lymph) becomes a critical aspect for
screening of potential candidates and their selection for in vivo studies. Among the alkyl ester
prodrugs, prodrug 1 (shortest alkyl ester) demonstrated the most efficient release of LPV in
plasma (Fig. 3C), and therefore was selected as a candidate for in vivo studies. Following the
results of the in vivo assessment of prodrug 1 (discussed below), activated ester prodrugs were
designed, synthesized and evaluated in vitro before potential selection for in vivo studies. The
release of LPV from activated ester prodrug 7 was more efficient than from prodrug 1 (86.6%
vs 6.5%) at 2 h time point (Fig. 3C), therefore this prodrug was chosen for the subsequent
studies. Taken together, high affinity to CMs, good stability in intestinal tract environment and
rapid conversion to active drug in lymphatics were considered the major requirements in
selection of prodrugs for in vivo studies.
4.3. In vitro antiretroviral activity of the selected prodrugs and released LPV
The in vitro antiretroviral efficacy tests confirm the need for the release of LPV from the
prodrugs for the efficacy against HIV-1 (Fig. 4A). This is not surprising, as LPV’s hydroxyl
group is a critical functional group for the inhibition of HIV-1 protease [50]. Prodrug 7 showed
significantly higher anti-HIV activity compared to prodrug 1, indicating the antiretroviral
activity of prodrugs in cell culture media was in fact closely linked to the amount of released
LPV (Fig. 4C). Previously published report suggests similar tendency for zidovudine prodrugs
[51]. To note, the in vitro IC50 cannot be directly translated to in vivo IC50, as LPV is highly
plasma protein bound drug (>99% [52]). It has been reported previously that a highly effective
32
viral inhibition is achieved at a plasma concentration higher than protein binding-adjusted IC90
(PA-IC90) of LPV for wild-type HIV-1 (140 ng/mL) [53].
4.4. Pharmacokinetics of selected prodrugs
The pharmacokinetic profiles following intravenous and oral administrations of prodrug 1
exhibited a prolonged exposure to the prodrug and released LPV in blood (Fig. 5C and 5D).
The long circulation time of the prodrug is likely due to the tissue distribution of highly
lipophilic prodrug 1, which is similar to other lipophilic, lymphatically transported compounds
[54,55]. Compared to relatively low released levels of LPV from prodrug 1 in systemic
circulation (Fig. 5C and 5D), activated ester prodrug 7 achieved higher systemic exposure to
LPV in vivo (Fig. 5E and 5F).
The increase in oral bioavailability of LPV achieved in this work is comparable to other studies
showing the increase in oral bioavailability of LPV using other approaches [56–58]. In a study
carried out by Patel et al. [56], a proliposome formulation of LPV led to increase in
bioavailability by 2.24-fold compared to pure LPV after oral administration in rats.
Furthermore, Patel et al. [57] and Negi et al. [58] reported 2.97- and 3.56-fold enhancement in
oral bioavailability using solid self-nanoemulsifying drug delivery system (S-SNEDDS) and
solid lipid nanoparticles (SLNs), respectively, compared to pure LPV following oral
administration in rats. In clinical practice, LPV is co-administered with a low dose of ritonavir,
a strong inhibitor of cytochrome P450 3A4 (CYP3A4), which results in increased plasma
exposure to LPV. However, co-administration of ritonavir with other drugs may lead to serious
drug-drug interactions (DDIs) mediated by inhibition of CYP3A4 [59,60]. Therefore, the
prodrug approach described in this work can lead, in addition to targeting viral reservoirs in
mesenteric lymph and MLNs (discussed below), to higher oral bioavailability of LPV without
DDIs issues in HIV-infected patients undergoing ritonavir-boosted lopinavir (LPV/r) regimen.
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4.5. Delivery of prodrugs and LPV to the viral reservoirs in the mesenteric lymphatic
system
Our results showed that the levels of LPV were below the limit of detection in both mesenteric
lymph and MLNs when unmodified LPV was administered orally, even in conditions
facilitating lymphatic transport (with lipids) (Fig. 6A). This indicates that oral administration
of unmodified LPV does not result in substantial intestinal lymphatic transport and therefore
cannot achieve protective concentration in lymphatic system to prevent HIV-1 replication. It is
clear that the concentrations of prodrugs 1 and 7 in mesenteric lymph and MLNs were
substantially higher than in plasma (Fig. 6B and 6D). However, the levels of released LPV
were higher in mesenteric lymphatic system following administration of prodrug 7 compared
to prodrug 1 (Fig. 7), probably due to the different LPV release rates (Fig. 3C). A similar
pattern of results was obtained in our previous work with anticancer compounds bexarotene
and retinoic acid, showing more efficient delivery of active drugs to the mesenteric lymphatic
system by activated ester prodrug approach compared to simple alkyl ester prodrug [29].
Although the extent of cumulative lymph transport was not directly measured in this study, we
would expect, based on lymph and plasma concentrations, the total amount of prodrug to access
the lymph to be similar to that described previously for simple esters [61] and lower than we
have described previously for cannabidiol and Δ9-tetrahydrocannabinol [30]. The advantage 
of the approach taken here, however, is that more effective release of active drug from prodrug
in case of activated ester leads to high levels of LPV in mesenteric lymph and MLNs.
Despite the importance of antiretroviral drugs delivery to viral reservoirs such as mesenteric
lymph and MLNs, there is a very limited number of studies in which the delivery of LPV to
the intestinal lymphatic system has been attempted. A number of publications have assessed
the potential of solid-lipid nanoparticles (SLNs) to improve the delivery of LPV to the
mesenteric lymphatic system [58,62–64]. It has been reported that the concentrations of LPV
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observed in MLNs were 3.4- [62] and 2.6-fold [63] higher, respectively, compared to those in
plasma 1 h following oral administration of LPV-loaded SLNs in rats. Other studies showed
that optimized SLNs approaches achieved 6.6- [64] and 9.1-fold [58] higher levels of LPV in
mesenteric lymph fluid, respectively, compared to plasma 2 h following oral administration of
LPV-loaded SLNs. Although it seems that SLNs indeed can increase the concentrations of LPV
in both mesenteric lymph and MLNs, it is unclear if LPV in these tissues is free or is still
encapsulated within the SLNs flowing through the intestinal lymphatics to the systemic
circulation. In the current study, we achieved 6.2- and 2.8-fold higher levels of released LPV
in mesenteric lymph, as well as 4.6- and 1.2-fold in MLNs, compared to those in plasma 3 h
following oral administration of lipophilic ester prodrugs 1 and 7, respectively (Fig. 6C and
6E). We have shown previously that drug associated with CMs (approach implemented in this
work) has full pharmacological access to lymphocytes [30], probably due to the activity of
lipoprotein lipase (LPL) interacting with Apo-C-II proteins on chylomicrons surface [65]. As
noted above, an effective viral inhibition is achieved at LPV concentration higher than PA-IC90
[53]. The levels of free released LPV from equivalent dose of both prodrugs 1 and 7 in
mesenteric lymphatic system substantially exceeds the critical PA-IC90 of 140 ng/mL (Fig. 7).




In this study, we proposed a highly lipophilic prodrug approach, combined with oral lipid-
based drug delivery to selectively and efficiently deliver LPV to the difficult-to-penetrate HIV
reservoirs in mesenteric lymphatic system. LPV has negligible CMs association, which indeed
results in the lack of substantial delivery of unmodified LPV to the mesenteric lymphatic
system even when administered with lipids promoting intestinal lymphatic absorption. Simple
alkyl ester prodrug approach resulted in substantially higher levels of the prodrug in mesenteric
lymphatic system compared to plasma, but poor release of active drug within the lymphatic
system. On the other hand, an activated ester prodrug approach showed good stability of the
prodrug in the intestinal tract and rapid release of LPV in lymphatic system, thereby leading to
high levels of LPV in the MLNs and mesenteric lymph. Moreover, oral administration of
activated ester prodrug also increased the oral bioavailability of LPV by nearly 2-fold, and
substantially prolonged the circulation time of LPV. This approach, especially if can be
translated to other antiretroviral drugs, has potential for reducing the size of HIV reservoirs
within the mesenteric lymphatic system.
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The ester prodrugs were synthesized following the procedure described in previous report [1]
with main difference being chromatography on silica was conducted with a mixture of
DCM/THF (5:1) as eluents. ¹H NMR and ¹³C NMR spectra (Bruker 400 Ultrashield
Spectrometer) were recorded at 400 and 100 MHz, respectively, at ambient temperature.
Chemical shifts (δ) were reported in parts per million (ppm) relative to DMSO-d6 (¹H, δ = 2.50 
ppm; ¹³C, δ = 39.52 ppm [2]). ¹H NMR data was reported as follows: chemical shift, integration, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet) and coupling
constants (J) were recorded in Hz. The spectra were analysed using MestReNova 12.0.1
software. High-resolution mass spectrometry was performed using a Bruker MicroTOF II with
electrospray ionisation (ESI). The liquid chromatograph-tandem mass spectrometry (LC-MS)
system consisted of a Shimadzu UFLCXR module equipped with an Applied Biosystems
API2000. An analytical C18 Gemini-NX column (50 mm × 2 mm I.D.) with a particle size of
3μm (Phenomenex, Macclesfield, UK) was used at 40°C to accomplish separation. All 
compounds were monitored at 220 nm (channel 2) and 254 nm (channel 1). Short gradient
method: pre-equilibration for 1 min at 5% solvent B, then increase to 98% B in 2 min, 98% B
for 2 min, decrease to 5% B in 0.5 min, then 5% B for 1 min. Long gradient method: pre-
equilibration for 1 min at 5% B, then 5% B for 0.5 min and increase to 98% B in 8 min, 98%
B for 2 min, decrease to 5% B in 0.5 min, then 5% for 1 min. Both methods underwent at flow
rate of 0.5 mL/min. Solvent A: 0.1% formic acid in water; solvent B: 0.1% formic acid in
acetonitrile. Thin-layer chromatography (TLC) was performed using Silica gel 60 Å F254
plates (Merck, Darmstadt, Germany). Compounds were purified via column chromatography
using ISOLUTE SPE columns (Flash Silica ΙΙ 5g/25mL) (Biotage, Hengoed, UK). Reagents 
and solvents for prodrugs characterization were purchased from Sigma-Aldrich (Gillingham,
UK) and Fisher Scientific (Leicestershire, UK), and were used without further purification.
Validation of the stability of prodrugs in rat plasma
The stability assessment was performed by spiking prodrug solution in acetonitrile into rat
plasma supplemented with 10 mg/mL of NaF. For the validation of prodrug 1, samples were
kept on ice for 5 min, followed by centrifugation (3000 g, 0°C, for 3 min) to mimic the
procedure of blood collection and plasma separation. Following centrifugation, the ‘separated
plasma’ samples were placed on ice for 1 h to mimic the time frame of temporary storage of
samples during pharmacokinetic studies, and then kept frozen at -80°C (for 24 h) until analysis.
For the validation of prodrug 7, plasma samples were kept on ice for 5 min and immediately
centrifuged (3000 g, 0°C, for 3 min). Following centrifugation, proteins were immediately
precipitated by 300 µL cooled (-20°C) acetonitrile and samples were processed for HPLC
analysis. Sample preparation procedure and chromatography conditions are described in
section 2.8 of the main manuscript. All experiments were performed in triplicates (data are
shown as mean ± SD). Tested prodrugs were stable at these conditions (97.6 ± 6.6% remaining
of prodrug 1; 92.3 ± 8.0% remaining of prodrug 7).
Validation of the stability of prodrug 7 in homogenized MLNs
Prodrug 7 solution was spiked into homogenized blank MLNs with water (1:3, w/v) and placed
on ice for 10 min (mimicking the time frame of lymph nodes isolation procedure), then stored
in dry ice for 1 h and transferred to -80°C (for 24 h) until analysis. Tested homogenates were
thawed at ambient temperature (containing 10 mg/mL of NaF), following by homogenization
on ice bath within 30 second to mimic the time frame of homogenization procedure. Sample
preparation procedure and chromatography conditions were described in section 2.8 of the
main manuscript. All experiments were performed in triplicates (data are shown as mean ± SD).
Prodrug 7 was stable in homogenized MLNs (93.9 ± 9.8% remaining).
Supplementary Material 2.
Characterization of ester prodrugs of lopinavir
1 (lopinavir butyl ester), (3S)-2-(2-(2, 6-dimethylphenoxy) acetamido)-5-((R)-3-methyl-2-(2-
oxotetrahydropyrimidin-1(2H)-yl) butanamido)-1, 6-diphenylhexan-3-yl butyrate was
synthesized using LPV and butyric acid as the reactants. The purity of the final compound was
more than 98% by HPLC-UV, white solid (85% yield), melting point 54.0-56.0°C. H¹ NMR
(400 MHz, DMSO-d6):  7.60-7.70 (m, 2H), 7.10-7.27 (m, 10H), 6.99-7.04 (m, 2H), 6.90-6.96
(m, 1H), 6.30 (s, 1H), 5.06-5.14 (m, 1H), 4.61-4.72 (m, 1H), 4.34 (d, J = 10.96 Hz, 1H), 4.13-
4.24 (m, 1H), 4.10 (s, 2H), 2.96-3.07 (m, 2H), 2.54-2.93 (m, 6H), 2.29-2.44 (m, 2H), 2.16 (s,
6H), 2.00-2.09 (m, 1H), 1.46-1.76 (m, 6H), 0.92 (t, J = 7.31 Hz, 3H), 0.83 (d, J = 6.4 Hz, 3H),
0.75 (d, J = 6.7 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d6):  172.31, 169.45, 167.68, 155.45,
154.69, 138.91, 138.41, 130.27, 129.12, 129.04, 128.79, 127.99, 127.9, 126.07, 125.61, 124.21,
72.74, 70.18, 61.46, 50.83, 46.64, 37.32, 37.18, 35.55, 25.40, 21.62, 19.59, 18.66, 18.00, 15.9,
13.5. HR-MS (ESI+): m/z [M+ H]+ calculated for C41H55N4O6, 699.4116, found 699.4102.
2 (lopinavir hexyl ester), (3S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-((S)-3-methyl-2-(2-
oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl hexanoate was
synthesized using LPV and hexanoic acid as the reactants. The purity of the final compound
was more than 98% by HPLC-UV, white solid (80% yield), melting point 52.0-54.0°C. H¹
NMR (400 MHz, DMSO-d6):  7.58-7.70 (m, 2H), 7.10-7.26 (m, 10H), 6.99-7.04 (m, 2H),
6.91-6.96 (m, 1H), 6.29 (s, 1H), 5.06-5.12 (m, 1H), 4.60-4.69 (m, 1H), 4.33 (d, J = 10.97 Hz,
1H), 4.12-4.22 (m, 1H), 4.09 (s, 2H), 2.96-3.05 (m, 2H), 2.54-2.92 (m, 6H), 2.30-2.43 (m, 2H),
2.15 (s, 6H), 1.89-1.99 (m, 1H), 1.55-1.76 (m, 4H), 1.19-1.32 (m, 6H), 0.80-0.86 (m, 6H), 0.74
(d, J = 6.65 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d6):  172.44, 169.44, 167.44, 155.43,
154.65, 138.91, 138.39, 130.26, 129.11, 129.03, 128.79, 128.00, 127.9, 126.08, 125.62, 124.22,
72.73, 70.16, 61.44, 50.83, 46.64, 37.31, 37.20, 33.63, 30.72, 25.41, 24.19, 21.81, 21.62, 19.59,
18.67, 15.89, 13.77. HR-MS (ESI+): m/z [M+ H]+ calculated for C43H59N4O6, 727.4429, found
727.4415.
3 (lopinaivr octyl ester), (3S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-((S)-3-methyl-2-(2-
oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl decanoate was
synthesized using LPV and octanoic acid as the reactants. The purity of the final compound
was more than 95% by HPLC-UV, colourless oil (65% yield). H¹ NMR (400 MHz, DMSO-
d6):  7.59-7.66 (m, 2H), 7.10-7.27 (m, 10H), 6.99-7.04 (m, 2H), 6.90-6.96 (m, 1H), 6.28 (s,
1H), 5.06-5.12 (m, 1H), 4.60-4.69 (m, 1H), 4.34 (d, J = 11.39 Hz, 1H), 4.12-4.19 (m, 1H), 4.09
(s, 2H), 2.96-3.06 (m, 2H), 2.54-2.92 (m, 6H), 2.34-2.41 (m, 2H), 2.15 (s, 6H), 1.99-2.05 (m,
1H), 1.55-1.74 (m, 4H), 1.19-1.30 (m, 10H), 0.80-0.85 (m, 6H), 0.74 (d, J = 6.9 Hz, 3H). ¹³C
NMR (100 MHz, DMSO-d6):  172.44, 169.42, 167.66, 155.43, 154.64, 138.90, 138.38,
130.26, 129.10, 129.03, 128.79, 128.00, 127.9, 126.1, 125.62, 124.23, 72.72, 70.15, 61.44,
50.83, 46.63, 37.33, 37.22, 33.70, 31.11, 28.88, 25.41, 24.62, 23.55, 21.62, 19.59, 18.66, 15.89,
13.77. HR-MS (ESI+): m/z [M+ H]+ calculated for C45H63N4O6, 755.4742, found 755.4737.
4 (lopinavir decanyl ester), (3S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-((S)-3-methyl-2-
(2-oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl dodecanoate was
synthesized using LPV and decanoic acid as the reactants. The purity of the final compound
was more than 95% by HPLC-UV, colourless oil (89% yield). H¹ NMR (400 MHz, DMSO-
d6):  7.58-7.67 (m, 2H), 7.10-7.26 (m, 10H), 6.99-7.04 (m, 2H), 6.90-6.96 (m, 1H), 6.29 (s,
1H), 5.05-5.12 (m, 1H), 4.61-4.70 (m, 1H), 4.34 (d, J = 11.07 Hz, 1H), 4.13-4.23 (m, 1H), 4.09
(s, 2H), 2.96-3.07 (m, 2H), 2.53-2.93 (m, 6H), 2.32-2.41 (m, 2H), 2.15 (s, 6H), 1.98-2.09 (m,
1H), 1.53-1.74 (m, 4H), 1.18-1.28 (m,14H), 0.81-0.86 (m, 6H), 0.74 (d, J = 6.65 Hz, 3H). ¹³C
NMR (100 MHz, DMSO-d6):  172.42, 169.43, 167.65, 155.44, 154.64, 138.90, 138.37,
130.24, 129.10, 129.02, 128.78, 127.98, 127.89, 126.09, 125.61, 124.22, 72.74, 70.15, 61.43,
50.82, 46.63, 37.34, 37.26, 33.70, 31.26, 28.92, 28.88, 28.52, 25.40, 24.52, 22.08, 21.62, 19.59,
18.65, 15.90, 13.92. HR-MS (ESI+): m/z [M+ H]+ calculated for C47H67N4O6, 783.5055, found
783.5035.
5 (lopinavir dodecanyl ester), (3S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-((S)-3-methyl-
2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl dodecanoate was
synthesized using LPV and dodecanoic acid as the reactants. The purity of the final compound
was more than 95% by HPLC-UV, colourless oil (85% yield). H¹ NMR (400 MHz, DMSO-
d6):  7.58-7.66 (m, 2H), 7.11-7.28 (m, 10H), 6.99-7.04 (m, 2H), 6.90-6.96 (m, 1H), 6.29 (s,
1H), 5.05-5.12 (m, 1H), 4.60-4.71 (m, 1H), 4.33 (d, J = 11.06 Hz, 1H), 4.12-4.22 (m, 1H), 4.09
(s, 2H), 2.97-3.05 (m, 2H), 2.54-2.92 (m, 6H), 2.34-2.41 (m, 2H), 2.15 (s, 6H), 1.99-2.07 (m,
1H), 1.55-1.74 (m, 4H), 1.18-1.26 (m, 18H), 0.80-0.86 (m, 6H), 0.74 (d, J = 6.6 Hz, 3H). ¹³C
NMR (100 MHz, DMSO-d6):  172.42, 169.42, 167.65, 155.43, 154.64, 138.90, 138.37,
130.24, 129.11, 129.02, 128.78, 127.98, 127.89, 126.08, 125.42, 124.21, 72.75, 70.15, 61.93,
50.82, 46.64, 37.35, 37.27, 33.71, 31.29, 28.99, 28.88, 28.71, 28.52, 25.41, 24.52, 22.09, 21.62,
19.59, 18.65, 15.90, 13.93. HR-MS (ESI+): m/z [M+ H]+ calculated for C49H71N4O6, 811.5368,
found 811.5374.
6 (lopinavir N-Acetylglycylglycinyl ester), (3S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-
((R)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl
acetylglycylglycinate was synthesized using LPV and 2-(2-acetamidoacetamido) acetic acid as
the reactants. The purity of the final compound was more than 95% by HPLC-UV, colourless
oil (46% yield). H¹ NMR (400 MHz, DMSO-d6):  8.32 (t, J = 5.9 Hz, 1H), 8.20 (t, J = 5.9 Hz,
1H), 7.70 (d, J = 9.7 Hz, 1H), 7.63 (d, J = 9.1 Hz, 1H), 7.10-7.25 (m, 10H), 7.00-7.02 (m, 2H),
6.90-6.94 (m, 1H), 6.28 (s, 1H), 5.05-5.09 (m, 1H), 4.70-4.77 (m, 1H), 4.33 (d, J = 11 Hz, 1H),
4.14-4.28 (m, 1H), 3.85-4.06 (m, 2H), 3.70-3.72 (m, 2H), 2.98-3.03 (m, 2H), 2.56-2.90 (m,
6H), 2.15 (s, 6H), 2.02-2.06 (m, 1H), 1.54-1.73 (m, 4H), 1.24-1.39 (m, 2H), 1.83 (s, 3H), 0.82
(d, J = 6.4 Hz, 3H), 0.74 (d, J = 6.7 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d6):  169.82, 169.69,
169.60, 169.30, 167.89, 155.42, 154.92, 138.87, 138.49, 130.32, 129.16, 129.01, 128.75,
127.99, 127.90, 126.05, 125.61, 124.13, 73.91, 70.28, 61.44, 50.51, 46.65, 41.98, 40.81, 37.28,
37.20, 29.03, 25.39, 22.44, 21.61, 19.63, 18.66, 15.96. HR-MS (ESI+): m/z [M+ H]+ calculated
for C43H57N6O8, 785.4232, found 785.4223.
7 (lopinavir butoxyacetyl ester), (2S,3S,5R)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-((S)-
3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamido)-1,6-diphenylhexan-3-yl 2-
butoxyacetate was synthesized using LPV and 2-butoxyacetic acid as the reactants. The purity
of the final compound was more than 98% by HPLC-UV, white solid (87% yield), melting
point 72.0-75.0°C. H¹ NMR (400 MHz, DMSO-d6):  7.68 (d, J = 9.1 Hz, 2H), 7.63 (d, J = 9.8
Hz, 1H), 7.11-7.28 (m, 10H), 7.00-7.02 (m, 2H), 6.91-6.95 (m, 1H), 6.30 (s, 1H), 5.13-5.17
(m, 1H), 4.66-4.73 (m, 1H), 4.35 (d, J = 11 Hz, 1H), 4.12-4.25 (m, 1H), 4.03 (quintet, J = 7.0
Hz, 2H), 3.46-3.51 (m, 2H), 2.99-3.04 (m, 2H), 2.57-2.92 (m, 6H), 2.14 (s, 6H), 1.99-2.07 (m,
1H), 1.55-1.77 (m, 4H), 1.15-1.53 (m, 6H), 0.82-0.86 (m, 6H), 0.75 (d, J = 6.7 Hz, 3H). ¹³C
NMR (100 MHz, DMSO-d6):  169.90, 169.53, 167.74, 155.44, 154.62, 138.86, 138.34,
130.29, 129.12, 129.02, 128.78, 128.01, 127.91, 126.11, 125.65, 124.24, 73.41, 70.44, 70.13,
61.46, 50.74, 46.68, 37.28, 37.22, 33.63, 31.22, 25.42, 21.63, 20.75, 19.59, 18.73, 18.67, 15.89,
13.66. HR-MS (ESI+): m/z [M+ H]+ calculated for C43H58N4O7, 743.4378, found 743.4384.
Supplementary Material Fig. S1.
Supplementary Material Fig. S1. HIV-1 (NL4-3) infectivity assay was performed using
Rev-A3R5-GFP cell line after drug (10-3–104 nM) treatment. The percentage of GFP+ cells
was measured by flow cytometry at 72 h post infection.
Supplementary Material Fig. S2
Supplementary Material Fig. S2. Assessment of the TG levels in biodistribution
studies in rats. Triglyceride (TG) levels obtained in mesenteric lymph following
oral administration of LPV (n = 4) and prodrugs 1 (n = 7) and 7 (n = 4) with lipids
(mean ± SD).













1, 6, 7 Gradient 1c C18 0.3 211 CBDg 50%
LPV, 2 Gradient 1d C18 0.3 211 CBD 50%
3 Gradient 1e C18 0.5 211 CBD 50%
4, 5 Gradient 3f C18 0.5 211 CBD 50%
a C18: Gemini C18 2.0 × 150 mm, 110Å, 5 µm particle size, coupled with a guard column (2 mm × 4mm) with a particle
size of 3 μm (Phenomenex, Macclesfield, UK). 
b Reconstitution solvent expressed as % of acetonitrile in HPLC-grade water.
c Gradient 1: Acetonitrile 50% at 0-9.5 min, increase to 65% at 9.5-11.5 min, 65% at 11.5-20 min, decrease to 50% at 20-
21 min, 50% at 21-25 min.
d Gradient 2: Acetonitrile 50% at 0-9.5 min, increase to 70% at 9.5-11.5 min, 70% at 11.5-20 min, decrease to 50% at 20-
21 min, 50% at 21-25 min.
e Gradient 3: Acetonitrile 50% at 0-6.5 min, increase to 80% at 6.5-10 min, 80% at 10-15 min, decrease to 50% at 15-16
min, 50% at 16-24 min.
f Gradient 4: Acetonitrile 50% at 0-6.5 min, increase to 85% at 6.5-10 min, 85% at 10-15 min, decrease to 50% at 15-16
min, 50% at 16-24 min.
g CBD: cannabidiol
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